Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

2

Portfolio Exits

2

About David Liu

David Liu, chief operating officer of Knewton and former Senior Vice President of AOL, is an angel investor.

David Liu Headquarter Location

New York, New York,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest David Liu News

David Liu's lab develops next-gen base editors, small enough to fit into single AAV

Jul 28, 2022

Aayushi Pratap News Reporter Researchers use adeno-associated viruses (AAVs) as vehicles to deliver CRISPR/Cas systems, correct gene copies and DNA and RNA sequences into human cells as treatment modalities. But the size of the viruses themselves has been a limiting factor for cargo that can be stuffed into it. For instance, gene-editing technologies such as CRISPR/Cas and base editors must be divided into two adenoviruses. Now, for the first-time, scientists have engineered a way to shrink base editors, allowing them to be loaded into a single virus particle. David Liu, from MIT and Harvard’s Broad Institute, led the research and published a paper Thursday in Nature Biomedical Engineering. Keep reading Endpoints with a free subscription Unlock this story instantly and join 146,500+ biopharma pros reading Endpoints daily — and it's free. SIGN UP John Carroll Editor & Founder With booming Shingrix sales filling its financial sails in the wake of the Haleon spinout , the executive team at New GSK repeatedly touted the blockbuster opportunity presented by their RSV vaccine during Q2 calls Wednesday, promising that the best is yet to come as they upped their guidance for the second half while raising the prospect of more M&A. “We are delivering,” CEO Emma Walmsley told analysts, with commercial momentum, pipeline advances and recent late-stage BD moves that are likely to be replicated before the year is out now that they have more flexibility after the Haleon spinout. Keep reading Endpoints with a free subscription Unlock this story instantly and join 146,500+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Kyle LaHucik Associate Editor Takeda has ended its work with Turnstone Biologics on a solid tumor asset that was in a Phase I/IIa study, upending a 2019 deal that had $900 million in biobucks on the line. The Japanese Big Pharma disclosed it was dropping TAK-605 and returning the armored oncolytic virus back to the New York biotech for “strategic reasons,” according to a quarterly update Thursday morning. Turnstone regains the global rights to the asset, also named RIVAL-01. Keep reading Endpoints with a free subscription Unlock this story instantly and join 146,500+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Paul Schloesser Associate Editor When AlphaFold first came out, it debuted with the promise of increasing the number of protein structures that could be predicted, a move that had eluded researchers for decades and could prove to become a crucial step to moving drug development to a new height. Now, AlphaFold says its database of protein structures has been massively expanded. Google’s AI outfit and the European Molecular Biology Laboratory’s European Bioinformatics Institute (EMBL-EBI) announced Thursday that DeepMind’s AlphaFold database now contains the structures of more than 200 million proteins. It’s a substantial jump from where it was a year ago when DeepMind announced that it had predicted the structure of only about 350,000 proteins. Keep reading Endpoints with a free subscription Unlock this story instantly and join 146,500+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Paul Schloesser Associate Editor Pennsylvania biotech Trevena put out word Thursday morning that it slashed 25% of its full-time staff and terminated a sales force agreement with Syneos, on top of a data readout it touted as positive. The biotech’s only approved product, marketed as Olinvyk, was OK’ed back in 2020 for moderate to severe acute pain. The opioid was originally spurned by the FDA back in 2018 after efficacy data was mixed compared to morphine at key doses and the agency wanted more safety data. Two years later, it got approved for use in a hospital setting, also getting a black box warning about addiction, abuse, respiratory depression and more. Read More

David Liu Investments

2 Investments

David Liu has made 2 investments. Their latest investment was in Welcome Commerce as part of their Seed VC on December 12, 2011.

CBI Logo

David Liu Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/21/2011

Seed VC

Welcome Commerce

$2M

Yes

1

5/21/2010

Seed VC

Subscribe to see more

$99M

Subscribe to see more

0

Date

12/21/2011

5/21/2010

Round

Seed VC

Seed VC

Company

Welcome Commerce

Subscribe to see more

Amount

$2M

$99M

New?

Yes

Subscribe to see more

Co-Investors

Sources

1

0

David Liu Portfolio Exits

2 Portfolio Exits

David Liu has 2 portfolio exits. Their latest portfolio exit was Welcome Commerce on November 08, 2018.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/8/2018

Acquired

$99M

3

2/7/2012

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/8/2018

2/7/2012

Exit

Acquired

Acquired

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Sources

3

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.